Bolt Biotherapeutics Q3 2023: cash $141.4M, BDC-1001 29% ORR, BDC-3042 dosed

Bolt Biotherapeutics, Inc.

2023-Q3 EPS reported -$1.36 revenue$5,787,000

Cash, cash equivalents and marketable securities of $141.4M as of Sept 30, 2023; expected to fund operations through 2025.
Collaboration revenue $2.5M (vs $2.1M Q3 2022); R&D expenses $15.0M (down from $19.0M).
Loss from operations of $18.2M vs $22.3M in prior year quarter.
BDC-1001 Phase 1 updated data: 29% ORR monotherapy; first complete response; well tolerated; Orphan Drug Designation for gastric cancers.
First patient dosed with BDC-3042 in Phase 1/2 for advanced solid tumors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bolt Biotherapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $2.5 million.

Period: the third quarter ended September 30, 2023
Revenue: $2.5 million
Result: reported results

Exact text from the filing

2023. Cash on hand is expected to fund multiple milestones and operations through 2025. Third Quarter 2023 Financial Results • Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022. Revenue in the comparative periods were generated from the services performed

View on SEC.gov

Browse all earnings releases →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.